Taylor Bear, MD
Neurology · Cleveland, TNNPI 1801019617
Payments from drug & device makers
Across 1,929 payments — averaging $146.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$149K
- Biohaven Pharmaceutical Holding Company Ltd.$53K
- Pfizer$40K
- Biohaven Pharmaceuticals, Inc.$14K
- UCB, Inc.$2K
- MDD US Operations, LLC$2K
- plus $23K from 54 others
Across 12 payments — averaging $3117.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$37K
What the payments were for
- Consulting fees$5,0009%
- Speaking & faculty fees$17,42431%
- Travel & lodging$3,1176%
- Food & beverage$30,51154%
- Education$1320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$283,262 in reported general payments places this provider in the 90th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $388,002 |
| VumerityDiroximel Fumarate | 22 | $258,213 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 14 | $170,968 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $162,773 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 16 | $130,943 |
| BotoxOnabotulinumtoxina | 72 | $103,017 |
| NuplazidPimavanserin Tartrate | 14 | $69,239 |
| AustedoDeutetrabenazine | 11 | $68,761 |
| Dimethyl Fumarate | 21 | $53,252 |
| AptiomEslicarbazepine Acetate | 21 | $48,116 |
| Nurtec OdtRimegepant Sulfate | 25 | $40,332 |
| Lacosamide | 73 | $20,484 |
| XcopriCenobamate | 15 | $19,037 |
| UbrelvyUbrogepant | 18 | $17,953 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $16,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $473 | $388,00217 claims |
| BiogenVumerity | $1,460 | $258,21322 claims |
| Grifols USA, LLCGamunex-C | $40 | $162,77315 claims |
| AbbVieBotox, Ubrelvy | $148,631 | $120,97190 claims |
| Acadia Pharmaceuticals IncNuplazid | $901 | $69,23914 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $593 | $68,76111 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $796 | $48,11621 claims |
| PfizerNurtec Odt | $40,208 | $40,33225 claims |
| SK Life Science, Inc.Xcopri | $326 | $19,03715 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $266 | $6,05037 claims |
| Upsher-smith Laboratories LLCTopiramate | $199 | $77971 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 361 neurology providers in Tennessee.
Other neurology in Cleveland
- Lee SteinCordova$22.6M
- Sibyl WrayKnoxville$21.6M
- Lora McGillMemphis$7.5M
- Thomas ArnoldCordova$5.5M
- Daniel ClaassenNashville$3.5M
- Samuel HunterSpring Hill$2.9M
- Randall TrudellKnoxville$2.8M
- Oleksandra DrynCordova$2.8M
- Siddharama PawateNashville$2M
- Anthony NicholasMemphis$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.